Skip to main content
F1000Research logoLink to F1000Research
. 2017 Jun 9;6:860. [Version 1] doi: 10.12688/f1000research.10692.1

Molecular and phenotypic biomarkers of aging

Xian Xia 1, Weiyang Chen 2, Joseph McDermott 1, Jing-Dong Jackie Han 1,a
PMCID: PMC5473407  PMID: 28663789

Abstract

Individuals of the same age may not age at the same rate. Quantitative biomarkers of aging are valuable tools to measure physiological age, assess the extent of ‘healthy aging’, and potentially predict health span and life span for an individual. Given the complex nature of the aging process, the biomarkers of aging are multilayered and multifaceted. Here, we review the phenotypic and molecular biomarkers of aging. Identifying and using biomarkers of aging to improve human health, prevent age-associated diseases, and extend healthy life span are now facilitated by the fast-growing capacity of multilevel cross-sectional and longitudinal data acquisition, storage, and analysis, particularly for data related to general human populations. Combined with artificial intelligence and machine learning techniques, reliable panels of biomarkers of aging will have tremendous potential to improve human health in aging societies.

Keywords: physiological age, phenotypic, molecular, age-associated diseases, aging process

Introduction: Why do we need biomarkers of aging?

Aging is the time-dependent physiological functional decline that affects most living organisms, which is underpinned by alterations within molecular pathways, and is also the most profound risk factor for many non-communicable diseases. To identify biomarkers of aging would, on one hand, facilitate differentiation of people who are of the same chronological age yet have variant aging rates. Quantitative biomarkers of aging could also define a panel of measurements for ‘healthy aging’ and, even further, predict life span. On the other hand, biomarkers of aging could also assist researchers to narrow their research scope to a specific biological facet in their attempts to explain the biological process behind aging or aging-related diseases. Here, we review the phenotypic and molecular biomarkers of aging. Phenotypic biomarkers can be non-invasive, panoramic, and easy to obtain, whereas molecular biomarkers can reflect some of the molecular mechanisms underlying age status. This review is centered on humans (with mouse and nematode in some rare cases).

Molecular biomarkers of aging

This section is inspired by two high-impact reviews on the hallmarks of aging 1, 2. Following the framework of these reviews, we focus on developments since 2013. The American Federation for Aging Research (AFAR) has proposed the following criteria for a biomarker of aging: (1) it must predict the rate of aging; (2) it must monitor a basic process that underlies the aging process, not the effects of disease; (3) it must be able to be tested repeatedly without harming the person; and (4) it must be something that works in humans and in laboratory animals.

Biomarkers fulfilling all of the criteria proposed by the AFAR are unlikely to exist 3, so in the molecular part of this review we follow the first two criteria: a biomarker should predict the rate of aging, and it must monitor a basic process that underlies the aging process. For the first criterion, we required the biomarker to be correlated with aging; for the second criterion, we have organized the first part of this review according to the molecular pathways underling aging.

DNA and chromosomes

Telomeres. Telomeres are ribonucleoprotein complexes at the end of chromosomes and become shorter after each replication, as telomerase, the enzyme responsible for its replication, is not regularly expressed in somatic cells 4. The length of telomeres in leukocytes has been associated with aging and life span 5 as well as age-related diseases, such as cardiovascular diseases 6, 7, cancer 8, and neurological disorders 9.

DNA repair. The link between DNA damage and repair has been implicated in aging by the accumulation of senescent cells 10 or genomic rearrangements 11. More recently, this link was directly demonstrated, and controlled induction of DNA double-strand breaks in mouse liver inducing aging pathologies and gene expression was shown 12. Immunohistochemistry of γ-H2A.X is an established quantitative biomarker of aging because H2A.X is a variant of the H2A protein family, and phosphorylated H2A.X, γ-H2A.X, is an initial and essential component of DNA damage foci and therefore a reliable marker of the extent of DNA damage 1315. Serum markers of DNA damage, including CRAMP, EF-1a, stathmin, N-acetyl-glucosaminidase, and chitinase, have also been established 16. Of note, the dermal fibroblasts from centenarian donors were shown to be less sensitive to H 2O 2-induced DNA damage than fibroblasts from young and old donors 17. Such ex vivo experiments could also be a potential biomarker of aging.

Epigenetic modifications. Age-related changes in DNA methylation patterns, notably as measured by the epigenetic clock, are among the best-studied aging biomarkers 1820. Analysis of methylation profiles in the blood found that only three CpG sites could predict age with a mean absolute deviation from chronological age of less than 5 years 21. The association between age and DNA methylation can be extended to age-associated diseases, such as diabetes 22. For a full review of the epigenetic regulation of aging, see Sen et al. 23.

RNA and transcriptome

Transcriptome profiles. With rapid progress in single-cell RNA sequencing (RNA-seq) technology, it has begun to be applied to the study of biomarkers of aging. Lu et al. have recently shown that cell-to-cell expression variation, as measured by single-cell RNA-seq of high-dimensional flow cytometry sorted T cells, is associated with aging and disease susceptibility 24.

A recent study used whole-blood gene expression profiles from 14,983 individuals to identify 1,497 genes with age-dependent differential expression and then used them to calculate the ‘transcriptomic age’ of an individual, suggesting that transcriptome signatures can be used to measure aging 25.

Non-coding RNAs. MicroRNAs (miRNAs) are a class of small (21- to 23-nucleotide) non-coding RNAs that, through base-pairing mechanisms, regulate a broad range of biological processes, including metabolism 26 and aging 27. Among them, circulating miRNAs can be stable in plasma by residing in exosomes or binding to protein or lipoprotein factors, thus making them easy-to-access biomarkers. miR-34a was the first observed circulating miRNA with an altered expression pattern during mouse aging 28. Its expression is found to correlate with age-related hearing loss in mice and humans 29. miR-21 was defined as an inflammatory biomarker in a study of 365 miRNAs in the plasma of healthy and old humans 30. miR-151a-3p, miR-181a-5p, and miR-1248 are reported to be significantly decreased with age in humans, in which all three miRNAs also show indications of associations with inflammation 31. miR-126-3p has been found to be positively correlated with age in 136 healthy subjects from 20 to 90 years of age 32. Through expression of GFP driven by miRNA promoters, Pincus et al. found that levels of mir-71, mir-246, and mir-239 in early adulthood vary across individuals and are predictive of life span 33. A recent review 27 summarized the associations of other types of circulating non-coding small RNAs, such as tRNA and YRNA.

Long non-coding RNAs (lncRNAs) are a heterogeneous class of non-coding RNAs which are defined as transcripts longer than 200 nucleotides and devoid of evident open reading frames 34. Two recent reviews summarize the role of lncRNAs in aging 35, 36. The diverse functional mechanisms of lncRNA are beyond the scope of this review, and readers may consult a recent review on this topic 37; here, we list lncRNAs that function in aging. The lncRNA MIR31HG was identified to be upregulated in oncogene-induced senescence and required for polycomb group–mediated repression of the INK4A locus 38. Downregulation of lncRNA AK156230 occurs in replicative senescence and its knockdown in mouse embryonic fibroblasts induces senescence through dysregulation of autophagy and cell cycle pathways, as shown by expression profiles 39. Meg3 is upregulated during cardiovascular aging as well as in senescent human umbilical venous endothelial cells 40. As most of the lncRNAs studies have been anecdotal, high-throughput lncRNA studies, such as CRISPR-Cas9 screen of functional lncRNAs 41, will be a useful future step toward understanding lncRNA functions in the aging process.

Metabolism

That dietary restriction is the most conserved means to extend life span and health span from yeast to mammals 42 points to a pivotal role of metabolism in aging regulation and to the potential for metabolic factors to be biomarkers.

Nutrient sensing. The insulin/insulin-like growth factor 1 (IGF-1) signaling (IIS) pathway, which participates in glucose sensing, is the earliest discovered and the most well-known pathway to antagonize longevity. Paradoxically, IGF-1 declines in wild-type mice or mouse models of premature aging whereas attenuating IIS activity extends life span 43. Such observations led to the potential inclusion of IIS pathway members, such as growth hormone and IGF-1, as biomarkers of aging 44, 45.

The mechanistic target of rapamycin (mTOR) protein senses high amino acid concentrations. Inhibition of mTOR can extend life span 46. Unlike the IIS pathway, mTOR activity increases with age in the ovarian surface epithelium of aged human and mouse ovaries, which contributes to pathological changes 47. Phosphorylated S6 ribosomal protein (p-S6RP, or pS6) is a downstream target and also a known marker of active mTOR signaling 47, 48, which is a potential biomarker of aging as indicated in the research of aged ovaries 47.

In contrast to IIS and mTOR function, 5′-adenosine monophosphate (AMP)–activated protein kinase (AMPK) and sirtuins sense nutrient scarcity instead of abundance. AMPK detects high AMP levels whereas sirtuins are sensors of high NAD + levels, and both mark low-energy states. The upregulation of AMPK activity by metformin, a drug for type II diabetes, could mimic some of the benefits of caloric restriction, and metformin extends life span in male mice 49. AMPK is upregulated with age in skeletal muscles 50.

Sirtuins have the ability to directly link cellular metabolic signaling (reflected by NAD +) to protein post-translational modifications through a chemical reaction (deacetylation of lysine). During aging, NAD + is reduced 51 and sirtuins are downregulated 52, 53. An analysis of primary human dermal fibroblasts found that SIRT1 and SIRT6 are downregulated through passaging 54. Similarly, levels of SIRT1, SIRT3, and SIRT6 detected by Western blotting showed significant decrease in ovaries of aged mice 55. In human peripheral blood mononuclear cells, SIRT2 also decreases with age 56.

Protein metabolism. Protein carbamylation is one of the non-enzymatic post-translational modifications which occur throughout the whole life span of an organism, leading to tissue accumulation of carbamylated proteins 57. It is considered a hallmark of molecular aging and is related to aging-related diseases, such as cardiovascular disease 58.

Advanced glycation end products (AGEs) are a heterogeneous group of bioactive molecules that are formed by non-enzymatic glycation of proteins, lipids, and nucleic acids 59. Accumulation of AGEs in aging tissues leads to inflammation 60, apoptosis 61, obesity 62, and other age-related disorders 63. AGEs can be detected via high-performance liquid chromatography, gas chromatography-mass spectrometry, and immunochemical techniques 64. N-glycans are a class of glycoproteins with sugar chains bonded to the amide nitrogen of asparagine. The spectrum of N-linked glycans (the N-glycome) can now be investigated because of the development of high-throughput methods. The accumulation of N-linked glycation at Asn297 of the Fc portion of IgG (IgG-G0) can contribute to low-grade pro-inflammatory status in aging 65.

Lipid metabolism. Triglycerides are found to increase monotonously with age and thus could be a biomarker of aging 66. Studies of serum samples by shotgun lipidomics found that phospho/sphingolipids are putative markers, and biological modulators, of healthy aging 67. However, the design of these studies is questionable in that they have a group of elderly individuals as a ‘not healthy aging control’ and compare them with the ‘successful aging’ centenarian group 67, 68, but the two groups are obviously of very different ages. Therefore, it is not clear whether it was the age difference or the success of healthy aging that contributed to the differences in lipidomics.

Oxidative stress and mitochondria

Biomarkers of oxidative stress have long been regarded as a class of aging biomarkers. The products of oxidative damage to proteins include o-tyrosine, 3-chlorotyrosine, and 3-nitrotyrosine. 8-iso prostaglandin F is a biomarker for phospholipid damage. 8-hydroxy-2′-deoxyguanosine and 8-hydroxyguanosine are produced by the oxidative damage of nucleic acids 69. The concentration of these biomarkers in body fluids can be detected via high-performance liquid chromatography and mass spectrometry. Shen et al. engineered a circularly permuted yellow fluorescent protein (cpYFP) expressed in Caenorhabditis elegans mitochondrial matrix as a sensor of oxidative stress and metabolic changes; the authors found that adult day 3 mitochondrial cpYFP flash frequency is a good predictor of C. elegans life span under different genetic, environmental, and stochastic conditions 70.

Although free radicals, the source of oxidative stress, are mainly produced in mitochondria, dysfunctional mitochondria can contribute to aging independently of reactive oxygen species. To measure mitochondria function, blood- and-muscle based respirometric profiling strategies are available, and the association of this potential reporter with bioenergetic capacity of other tissues 71 or phenotypes, such as gait speed 72, has been investigated. Extracellular mitochondria components can function as damage-associated molecular pattern molecules (DAMPs) (see also “Inflammation and intercellular communication”) and these induce neuroinflammation when injected in mouse hippocampus 73.

Cell senescence

In mitotic tissues, the gradual accumulation of senescent cells is thought be one of the causal factors of aging 7476. Thus, the biomarkers of cell senescence can also be used as markers. Such biomarkers have been summarized in recent reviews 77, 78. The most widely used marker is senescence-associated β-galactosidase (SAβ-gal) 79 and p16 INK4A 80, 81. SAβ-gal reflects increased lysosomal mass 82 but can yield false positives because of its low specificity 83. SAβ-gal is a cell damage marker, and p16 INK4A is required to induce, and is indicative of, permanent cell cycle arrest 81.

Other senescent cell markers include activated and persistent DNA-damage response (see “DNA repair”), telomere shortening and dysfunction (see “Telomere”), and senescence-associated secretory phenotype (SASP) (see “Inflammation and intercellular communication”).

Inflammation and intercellular communication

SASP is a consequence of cell senescence and may occur in cells that, though undergoing cell cycle arrest, are still metabolically active and secrete proteins. SASP functions in an autocrine/paracrine manner 84, 85. The major components of SASP factors are soluble signaling factors, including interleukins, chemokines, and growth factors. Proteins that are associated with the SASP, such as interleukin-6, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, matrix metalloproteinases, and IGF binding proteins, increase in multiple tissues with chronological aging and occur in conjunction with sterile inflammation 86. Comprehensive catalogs of SASP also include secreted proteases and secreted insoluble proteins/extracellular matrix components and are summarized by Coppé et al. 87 and the Reactome database ( http://www.reactome.org/content/detail/R-HSA-2559582).

The DAMPs, such as heat shock proteins, histones, high-mobility group box 1, and S100, compose a class of molecules released after injury or cellular death 88 and mediate immune response. The association between DAMPs and other hallmarks of aging has been reviewed by Huang et al. 89.

Phenotypic biomarkers of aging

Still following the criteria proposed by the AFAR 3, here we categorize the phenotypic biomarkers of aging. It is difficult for phenotypic biomarkers to monitor a basic molecular process that underlies the aging process, so we follow three standards: a biomarker should predict rate of aging, it must be able to be tested repeatedly without harming the person, and it monitors one or more physiological processes.

Physical function and anthropometry are the most practical measurements among phenotypic biomarkers of aging. In this regard, walking speed, chair stand, standing balance, grip strength, body mass index, waist circumference, and muscle mass are well known 90. These physical functional measurements, though simple, can actually perform better than DNA methylation in terms of relationship to health status in demographic research 91.

Quantitative phenotypes of external human features also show significant relationships with aging 92, 93. Quantified facial features based on three-dimensional (3D) facial images, such as mouth width, nose width, and eye corner droop, are highly associated with age. In fact, 3D facial images can be used to quantify the biological age of an individual 92.

Integration of aging biomarkers

Biomarkers of aging can be used to predict the physiological age, which reflects their state of health, via statistics and machine learning algorithms. A single class of biomarkers, which is intrinsically a matrix of features, can be used in the prediction. DNA methylation was used to predict age with an error of about 3.6 years using 8,000 samples 94. 3D facial images have also been used to predict age with a mean deviation of 6 years 92.

Integration of multiple biomarkers can be even more powerful. The Dunedin Study 91 has focused on middle-aged people and used different measurements (telomere lengths, epigenetic clocks, and clinical biomarker composites) and compared their performance in predicting health status, as measured by physical functionality, cognitive decline, and subjective signs of aging. The three types of measurements in this study do not correlate with each other, suggesting that there is no single index of biological age. Therefore, another approach is to use statistic distance, D M 95, 96, to assess the degree of deviation of an individual’s biomarker profile from the reference population. D M is the Mahalanobis distance 97 of multi-variants (in the simplest case, when all the variants are uncorrelated, this distance is the sum of the absolute values of z-scores), and is proven to be insensitive to biomarker choice across 44 available markers and to be generalizable with multiple marker variants. Recently, a modular ensemble of 21 deep neural networks was used to predict age by using measurements from basic blood tests by training over 60,000 samples, which revealed the five most important blood markers for predicting human chronological age: albumin, glucose, alkaline phosphatase, urea, and erythrocytes 98.

Conclusion and outlook

As expected from the complex nature of the aging process, aging biomarkers are multilayered and multifaceted and consist of a dizzying array of parameters, which we further summarized in an even more concise form as a table ( Table 1). This, however, does not mean that they are equally useful. We need to point out that not all factors, although they might be involved in the underling biological process of aging, are proven to be useful in terms of measuring human aging at this point.

Table 1. Biomarkers of aging.

For species source, if there is one in humans, then other model organisms are omitted.

Biomarker
Category
Biomarker
Subcategory
Biomarker Trend with age Species
Molecular biomarkers DNA and
chromosome
Telomere Leukocyte telomere length Decrease Human
DNA repair γ-H2A.X immunohistochemistry Increase Human
Epigenetic
modification
DNA methylation Global hypomethylation and
local hypermethylation
Human
RNA and
transcriptome
Transcriptome profiles Heterogeneity of CD38 in CD4 +CD27 +
T cells
Decrease Human
Heterogeneity of CD197 in CD4 +CD25 +
T cells
Increase Human
Circulating microRNAs
(miRNAs)
miR-34a, miR-21, miR-126-3p Increase Human
miR-151a-3p, miR-181a-5p, miR-1248 Decrease Human
Long non-coding
RNAs
MIR31HG Increase in cell senescence Human
AK156230 Decrease in cell senescence Mouse
Meg3 Increase in cell senescence Human
Metabolism Nutrient sensing Growth hormone and insulin/insulin-
like growth factor 1 (IGF-1)
Decrease Human
Mechanistic target of rapamycin
(mTOR) and pS6RP
Increase Human
NAD +, SIRT1, SIRT2, SIRT3, SIRT6 Decrease Human
Protein metabolism Protein carbamylation, such as
homocitrulline rate
Increase Human
Advanced glycation end products
and N-glycans
Increase Human
Lipid metabolism Triglycerides Increase Human
Oxidative stress
and mitochondria
o-tyrosine, 3-chlorotyrosine,
3-nitrotyrosine, 8-iso prostaglandin
F2α, 8-hydroxy-2′-deoxyguanosine,
8-hydroxyguanosine
Increase Human
Cell senescence Senescence-associated
β-galactosidase
Increase in cell senescence Human
p16INK4A Increase in cell senescence Human
Inflammation
and intercellular
communication
Senescence-associated secretory
phenotype
Increase Human
Phenotypic
biomarkers
Physical function and
anthropometry
Walking speed, chair stand, standing
balance, grip strength, muscle mass
Decrease
Body mass index, waist circumference Increase
Facial features Mouth width Increase
Nose width Increase
Mouth-nose distance Increase
Eye corner slope Decrease

Recently, the MARK-AGE project was announced as a large-scale integrated project aimed to find a powerful set of biomarkers for human aging based on over 3,200 subjects 99. Although more details from this project remain to be seen, the pace of identifying and using biomarkers of aging to improve human health, preventing aging-associated diseases, and extending healthy life span will only be further increased by the myriad of data generated. These include not only data from large human cohort studies but also ordinary people’s genomic, functional genomic, phenotypic, and lifestyle data, which will be facilitated by the ever-growing capacity of data acquisition, storage, and analysis. It would not be far-fetched for there one day to be an artificial intelligence program capable of precise prognosis of how long a person can live, based on his or her quantitative measurements in a large panel of biomarkers of aging.

Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

  • Kristina Endres, Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Untere Zahlbacher Strasse 8, 55131 Mainz, Germany

  • Alan Cohen, Groupe de recherche PRIMUS, Department of Family Medicine, University of Sherbrooke, Sherbrooke, Quebec, Canada

  • Eileen Crimmins, Davis School of Gerontology, University of Southern California, Los Angeles, California, USA

Funding Statement

This work was supported by grants from the China Ministry of Science and Technology (2015CB964803 and 2016YFE0108700) and the National Natural Science Foundation of China (91329302, 31210103916, and 91519330) and the Chinese Academy of Sciences XDB19020301 and XDA01010303 to J-DJH.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 1; referees: 3 approved]

References

  • 1. López-Otín C, Blasco MA, Partridge L, et al. : The hallmarks of aging. Cell. 2013;153(6):1194–217. 10.1016/j.cell.2013.05.039 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 2. Engelfriet PM, Jansen EH, Picavet HS, et al. : Biochemical markers of aging for longitudinal studies in humans. Epidemiol Rev. 2013;35(1):132–51. 10.1093/epirev/mxs011 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 3. Johnson TE: Recent results: biomarkers of aging. Exp Gerontol. 2006;41(12):1243–6. 10.1016/j.exger.2006.09.006 [DOI] [PubMed] [Google Scholar]
  • 4. Aubert G, Lansdorp PM: Telomeres and aging. Physiol Rev. 2008;88(2):557–79. 10.1152/physrev.00026.2007 [DOI] [PubMed] [Google Scholar]
  • 5. Kimura M, Hjelmborg JV, Gardner JP, et al. : Telomere length and mortality: a study of leukocytes in elderly Danish twins. Am J Epidemiol. 2008;167(7):799–806. 10.1093/aje/kwm380 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 6. Rehkopf DH, Needham BL, Lin J, et al. : Leukocyte Telomere Length in Relation to 17 Biomarkers of Cardiovascular Disease Risk: A Cross-Sectional Study of US Adults. PLoS Med. 2016;13(11):e1002188. 10.1371/journal.pmed.1002188 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 7. Hammadah M, Al Mheid I, Wilmot K, et al. : Telomere Shortening, Regenerative Capacity, and Cardiovascular Outcomes. Circ Res. 2017;120(7):1130–8. 10.1161/CIRCRESAHA.116.309421 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 8. Blackburn EH, Epel ES, Lin J: Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193–8. 10.1126/science.aab3389 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 9. Eitan E, Hutchison ER, Mattson MP: Telomere shortening in neurological disorders: an abundance of unanswered questions. Trends Neurosci. 2014;37(5):256–63. 10.1016/j.tins.2014.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Sedelnikova OA, Horikawa I, Zimonjic DB, et al. : Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol. 2004;6(2):168–70. 10.1038/ncb1095 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 11. Dollé ME, Giese H, Hopkins CL, et al. : Rapid accumulation of genome rearrangements in liver but not in brain of old mice. Nat Genet. 1997;17(4):431–4. 10.1038/ng1297-431 [DOI] [PubMed] [Google Scholar]
  • 12. White RR, Milholland B, de Bruin A, et al. : Controlled induction of DNA double-strand breaks in the mouse liver induces features of tissue ageing. Nat Commun. 2015;6:6790. 10.1038/ncomms7790 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 13. Wang C, Jurk D, Maddick M, et al. : DNA damage response and cellular senescence in tissues of aging mice. Aging Cell. 2009;8(3):311–23. 10.1111/j.1474-9726.2009.00481.x [DOI] [PubMed] [Google Scholar]
  • 14. Rübe CE, Fricke A, Widmann TA, et al. : Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS One. 2011;6(3):e17487. 10.1371/journal.pone.0017487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Kuo LJ, Yang LX: Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22(3):305–9. [PubMed] [Google Scholar]
  • 16. Song Z, von Figura G, Liu Y, et al. : Lifestyle impacts on the aging-associated expression of biomarkers of DNA damage and telomere dysfunction in human blood. Aging Cell. 2010;9(4):607–15. 10.1111/j.1474-9726.2010.00583.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chevanne M, Caldini R, Tombaccini D, et al. : Comparative levels of DNA breaks and sensitivity to oxidative stress in aged and senescent human fibroblasts: a distinctive pattern for centenarians. Biogerontology. 2003;4(2):97–104. 10.1023/A:1023399820770 [DOI] [PubMed] [Google Scholar]
  • 18. Day K, Waite LL, Thalacker-Mercer A, et al. : Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biol. 2013;14(9):R102. 10.1186/gb-2013-14-9-r102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Horvath S, Zhang Y, Langfelder P, et al. : Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012;13(10):R97. 10.1186/gb-2012-13-10-r97 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Horvath S, Gurven M, Levine ME, et al. : An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. Genome Biol. 2016;17(1):171. 10.1186/s13059-016-1030-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Weidner CI, Lin Q, Koch CM, et al. : Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol. 2014;15(2):R24. 10.1186/gb-2014-15-2-r24 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Bacos K, Gillberg L, Volkov P, et al. : Blood-based biomarkers of age-associated epigenetic changes in human islets associate with insulin secretion and diabetes. Nat Commun. 2016;7: 11089. 10.1038/ncomms11089 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 23. Sen P, Shah PP, Nativio R, et al. : Epigenetic Mechanisms of Longevity and Aging. Cell. 2016;166(4):822–39. 10.1016/j.cell.2016.07.050 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 24. Lu Y, Biancotto A, Cheung F, et al. : Systematic Analysis of Cell-to-Cell Expression Variation of T Lymphocytes in a Human Cohort Identifies Aging and Genetic Associations. Immunity. 2016;45(5):1162–75. 10.1016/j.immuni.2016.10.025 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 25. Peters MJ, Joehanes R, Pilling LC, et al. : The transcriptional landscape of age in human peripheral blood. Nat Commun. 2015;6: 8570. 10.1038/ncomms9570 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 26. Dumortier O, Hinault C, Van Obberghen E: MicroRNAs and metabolism crosstalk in energy homeostasis. Cell Metab. 2013;18(3):312–24. 10.1016/j.cmet.2013.06.004 [DOI] [PubMed] [Google Scholar]
  • 27. Dhahbi JM: Circulating small noncoding RNAs as biomarkers of aging. Ageing Res Rev. 2014;17:86–98. 10.1016/j.arr.2014.02.005 [DOI] [PubMed] [Google Scholar]
  • 28. Li X, Khanna A, Li N, et al. : Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging. Aging (Albany NY). 2011;3(10):985–1002. 10.18632/aging.100371 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Pang J, Xiong H, Yang H, et al. : Circulating miR-34a levels correlate with age-related hearing loss in mice and humans. Exp Gerontol. 2016;76:58–67. 10.1016/j.exger.2016.01.009 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 30. Olivieri F, Spazzafumo L, Santini G, et al. : Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech Ageing Dev. 2012;133(11–12):675–85. 10.1016/j.mad.2012.09.004 [DOI] [PubMed] [Google Scholar]
  • 31. Noren Hooten N, Fitzpatrick M, Wood WH, 3rd, et al. : Age-related changes in microRNA levels in serum. Aging (Albany NY). 2013;5(10):725–40. 10.18632/aging.100603 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Olivieri F, Bonafè M, Spazzafumo L, et al. : Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging (Albany NY). 2014;6(9):771–87. 10.18632/aging.100693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Pincus Z, Smith-Vikos T, Slack FJ: MicroRNA predictors of longevity in Caenorhabditis elegans. PLoS Genet. 2011;7(9):e1002306. 10.1371/journal.pgen.1002306 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 34. Fatica A, Bozzoni I: Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. 10.1038/nrg3606 [DOI] [PubMed] [Google Scholar]
  • 35. Grammatikakis I, Panda AC, Abdelmohsen K, et al. : Long noncoding RNAs(lncRNAs) and the molecular hallmarks of aging. Aging (Albany NY). 2014;6(12):992–1009. 10.18632/aging.100710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Kour S, Rath PC: Long noncoding RNAs in aging and age-related diseases. Ageing Res Rev. 2016;26:1–21. 10.1016/j.arr.2015.12.001 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 37. Quinn JJ, Chang HY: Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62. 10.1038/nrg.2015.10 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 38. Montes M, Nielsen MM, Maglieri G, et al. : The lncRNA MIR31HG regulates p16 INK4A expression to modulate senescence. Nat Commun. 2015;6:6967. 10.1038/ncomms7967 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 39. Chen YN, Cai MY, Xu S, et al. : Identification of the lncRNA, AK156230, as a novel regulator of cellular senescence in mouse embryonic fibroblasts. Oncotarget. 2016;7(33):52673–84. 10.18632/oncotarget.10170 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 40. Boon RA, Hofmann P, Michalik KM, et al. : Long Noncoding RNA Meg3 Controls Endothelial Cell Aging and Function: Implications for Regenerative Angiogenesis. J Am Coll Cardiol. 2016;68(23):2589–91. 10.1016/j.jacc.2016.09.949 [DOI] [PubMed] [Google Scholar]
  • 41. Zhu S, Li W, Liu J, et al. : Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34(12):1279–86. 10.1038/nbt.3715 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 42. Fontana L, Partridge L, Longo VD: Extending healthy life span--from yeast to humans. Science. 2010;328(5976):321–6. 10.1126/science.1172539 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Schumacher B, van der Pluijm I, Moorhouse MJ, et al. : Delayed and accelerated aging share common longevity assurance mechanisms. PLoS Genet. 2008;4(8):e1000161. 10.1371/journal.pgen.1000161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Corpas E, Harman SM, Blackman MR: Human growth hormone and human aging. Endocr Rev. 1993;14(1):20–39. 10.1210/edrv-14-1-20 [DOI] [PubMed] [Google Scholar]
  • 45. Crimmins E, Vasunilashorn S, Kim JK, et al. : Biomarkers related to aging in human populations. Adv Clin Chem. 2008;46:161–216. 10.1016/S0065-2423(08)00405-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Johnson SC, Rabinovitch PS, Kaeberlein M: mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338–45. 10.1038/nature11861 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Bajwa P, Nagendra PB, Nielsen S, et al. : Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium. Oncotarget. 2016;7(15):19214–27. 10.18632/oncotarget.8468 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 48. Dieterlen MT, Bittner HB, Klein S, et al. : Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood. Cytometry B Clin Cytom. 2012;82(3):151–7. 10.1002/cyto.b.21005 [DOI] [PubMed] [Google Scholar]
  • 49. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. : Metformin improves healthspan and lifespan in mice. Nat Commun. 2013;4: 2192. 10.1038/ncomms3192 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 50. Gordon SE, Lake JA, Westerkamp CM, et al. : Does AMP-activated protein kinase negatively mediate aged fast-twitch skeletal muscle mass? Exerc Sport Sci Rev. 2008;36(4):179–86. 10.1097/JES.0b013e3181877e13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Massudi H, Grant R, Braidy N, et al. : Age-associated changes in oxidative stress and NAD + metabolism in human tissue. PLoS One. 2012;7(7):e42357. 10.1371/journal.pone.0042357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Dang W: The controversial world of sirtuins. Drug Discov Today Technol. 2014;12:e9–e17. 10.1016/j.ddtec.2012.08.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Imai S, Guarente L: NAD + and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–71. 10.1016/j.tcb.2014.04.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Kim KS, Park HK, Lee JW, et al. : Investigate correlation between mechanical property and aging biomarker in passaged human dermal fibroblasts. Microsc Res Tech. 2015;78(4):277–82. 10.1002/jemt.22472 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 55. Zhang J, Fang L, Lu Z, et al. : Are sirtuins markers of ovarian aging? Gene. 2016;575(2 Pt 3):680–6. 10.1016/j.gene.2015.09.043 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 56. Yudoh K, Karasawa R, Ishikawa J: Age-related Decrease of Sirtuin 2 Protein in Human Peripheral Blood Mononuclear Cells. Curr Aging Sci. 2015;8(3):256–8. 10.2174/1874609808999150831112939 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 57. Gorisse L, Pietrement C, Vuiblet V, et al. : Protein carbamylation is a hallmark of aging. Proc Natl Acad Sci U S A. 2016;113(5):1191–6. 10.1073/pnas.1517096113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Verbrugge FH, Tang WH, Hazen SL: Protein carbamylation and cardiovascular disease. Kidney Int. 2015;88(3):474–8. 10.1038/ki.2015.166 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 59. Semba RD, Nicklett EJ, Ferrucci L: Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med Sci. 2010;65(9):963–75. 10.1093/gerona/glq074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging. 1996;9(2):69–77. 10.2165/00002512-199609020-00001 [DOI] [PubMed] [Google Scholar]
  • 61. Hanssen NM, Wouters K, Huijberts MS, et al. : Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J. 2014;35(17):1137–46. 10.1093/eurheartj/eht402 [DOI] [PubMed] [Google Scholar]
  • 62. Sayej WN, Knight Iii PR, Guo WA, et al. : Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice. Biomed Res Int. 2016;2016: 7867852. 10.1155/2016/7867852 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 63. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223–34. 10.1146/annurev.med.46.1.223 [DOI] [PubMed] [Google Scholar]
  • 64. Nagai R, Shirakawa J, Ohno R, et al. : Antibody-based detection of advanced glycation end-products: promises vs. limitations. Glycoconj J. 2016;33(4):545–52. 10.1007/s10719-016-9708-9 [DOI] [PubMed] [Google Scholar]
  • 65. Dall'Olio F, Vanhooren V, Chen CC, et al. : N-glycomic biomarkers of biological aging and longevity: a link with inflammaging. Ageing Res Rev. 2013;12(2):685–98. 10.1016/j.arr.2012.02.002 [DOI] [PubMed] [Google Scholar]
  • 66. Glei DA, Goldman N, Lin YH, et al. : Age-Related Changes in Biomarkers: Longitudinal Data from a Population-Based Sample. Res Aging. 2011;33(3):312–26. 10.1177/0164027511399105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Montoliu I, Scherer M, Beguelin F, et al. : Serum profiling of healthy aging identifies phospho- and sphingolipid species as markers of human longevity. Aging (Albany NY). 2014;6(1):9–25. 10.18632/aging.100630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, et al. : A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging. Age (Dordr). 2015;37(3):9776. 10.1007/s11357-015-9776-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Syslová K, Böhmová A, Mikoška M, et al. : Multimarker screening of oxidative stress in aging. Oxid Med Cell Longev. 2014;2014: 562860. 10.1155/2014/562860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Shen EZ, Song CQ, Lin Y, et al. : Mitoflash frequency in early adulthood predicts lifespan in Caenorhabditis elegans. Nature. 2014;508(7494):128–32. 10.1038/nature13012 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 71. Tyrrell DJ, Bharadwaj MS, Jorgensen MJ, et al. : Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: Implications for a minimally invasive biomarker of mitochondrial health. Redox Biol. 2016;10:65–77. 10.1016/j.redox.2016.09.009 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 72. Tyrrell DJ, Bharadwaj MS, Van Horn CG, et al. : Respirometric Profiling of Muscle Mitochondria and Blood Cells Are Associated With Differences in Gait Speed Among Community-Dwelling Older Adults. J Gerontol A Biol Sci Med Sci. 2015;70(11):1394–9. 10.1093/gerona/glu096 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 73. Wilkins HM, Koppel SJ, Weidling IW, et al. : Extracellular Mitochondria and Mitochondrial Components Act as Damage-Associated Molecular Pattern Molecules in the Mouse Brain. J Neuroimmune Pharmacol. 2016;11(4):622–8. 10.1007/s11481-016-9704-7 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 74. Burton DG: Cellular senescence, ageing and disease. Age (Dordr). 2009;31(1):1–9. 10.1007/s11357-008-9075-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Campisi J: Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685–705. 10.1146/annurev-physiol-030212-183653 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Tacutu R, Budovsky A, Yanai H, et al. : Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective. Aging (Albany NY). 2011;3(12):1178–91. 10.18632/aging.100413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Sharpless NE, Sherr CJ: Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15(7):397–408. 10.1038/nrc3960 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 78. Matjusaitis M, Chin G, Sarnoski EA, et al. : Biomarkers to identify and isolate senescent cells. Ageing Res Rev. 2016;29:1–12. 10.1016/j.arr.2016.05.003 [DOI] [PubMed] [Google Scholar]; F1000 Recommendation
  • 79. Dimri GP, Lee X, Basile G, et al. : A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995;92(20):9363–7. 10.1073/pnas.92.20.9363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Liu Y, Sanoff HK, Cho H, et al. : Expression of p16 INK4a in peripheral blood T-cells is a biomarker of human aging. Aging Cell. 2009;8(4):439–48. 10.1111/j.1474-9726.2009.00489.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Vandenberk B, Brouwers B, Hatse S, et al. : p16 INK4a: A central player in cellular senescence and a promising aging biomarker in elderly cancer patients. J Geriatr Oncol. 2011;2(4):259–69. 10.1016/j.jgo.2011.08.004 [DOI] [Google Scholar]
  • 82. Kurz DJ, Decary S, Hong Y, et al. : Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113(Pt 20):3613–22. [DOI] [PubMed] [Google Scholar]
  • 83. Yang NC, Hu ML: The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp Gerontol. 2005;40(10):813–9. 10.1016/j.exger.2005.07.011 [DOI] [PubMed] [Google Scholar]
  • 84. Schadendorf D, Möller A, Algermissen B, et al. : IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol. 1993;151(5):2667–75. [PubMed] [Google Scholar]
  • 85. Wajapeyee N, Serra RW, Zhu X, et al. : Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132(3):363–74. 10.1016/j.cell.2007.12.032 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 86. Tchkonia T, Zhu Y, van Deursen J, et al. : Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123(3):966–72. 10.1172/JCI64098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Coppé JP, Desprez PY, Krtolica A, et al. : The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. 10.1146/annurev-pathol-121808-102144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Bianchi ME: DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1–5. 10.1189/jlb.0306164 [DOI] [PubMed] [Google Scholar]
  • 89. Huang J, Xie Y, Sun X, et al. : DAMPs, ageing, and cancer: The 'DAMP Hypothesis'. Ageing Res Rev. 2015;24(Pt A):3–16. 10.1016/j.arr.2014.10.004 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 90. Wagner KH, Cameron-Smith D, Wessner B, et al. : Biomarkers of Aging: From Function to Molecular Biology. Nutrients. 2016;8(6): pii: E338. 10.3390/nu8060338 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Belsky DW, Moffitt TE, Cohen AA, et al. : Telomere, epigenetic clock, and biomarker-composite quantifications of biological aging: Do they measure the same thing? bioRxiv. 2016. 10.1101/071373 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 92. Chen W, Qian W, Wu G, et al. : Three-dimensional human facial morphologies as robust aging markers. Cell Res. 2015;25(5):574–87. 10.1038/cr.2015.36 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Chen W, Xia X, Huang Y, et al. : Bioimaging for quantitative phenotype analysis. Methods. 2016;102:20–5. 10.1016/j.ymeth.2016.01.017 [DOI] [PubMed] [Google Scholar]
  • 94. Horvath S: DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115. 10.1186/gb-2013-14-10-r115 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 95. Cohen AA, Milot E, Yong J, et al. : A novel statistical approach shows evidence for multi-system physiological dysregulation during aging. Mech Ageing Dev. 2013;134(3–4):110–7. 10.1016/j.mad.2013.01.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Cohen AA, Li Q, Milot E, et al. : Statistical distance as a measure of physiological dysregulation is largely robust to variation in its biomarker composition. PLoS One. 2015;10(4):e0122541. 10.1371/journal.pone.0122541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. De Maesschalck R, Jouan-Rimbaud D, Massart DL: The Mahalanobis distance. Chemometr Intell Lab Syst. 2000;50(1):1–18. 10.1016/S0169-7439(99)00047-7 [DOI] [Google Scholar]
  • 98. Putin E, Mamoshina P, Aliper A, et al. : Deep biomarkers of human aging: Application of deep neural networks to biomarker development. Aging (Albany NY). 2016;8(5):1021–33. 10.18632/aging.100968 [DOI] [PMC free article] [PubMed] [Google Scholar]; F1000 Recommendation
  • 99. Bürkle A, Moreno-Villanueva M, Bernhard J, et al. : MARK-AGE biomarkers of ageing. Mech Ageing Dev. 2015;151:2–12. 10.1016/j.mad.2015.03.006 [DOI] [PubMed] [Google Scholar]

Articles from F1000Research are provided here courtesy of F1000 Research Ltd

RESOURCES